Gene · 4880
NPPC: natriuretic peptide C
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. NPPC: natriuretic peptide C. Genes, record 4880. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/4880
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P23582 | C-type natriuretic peptide | 126 | 1 | Ensembl, GeneID, HGNC |
Source UniProt
Patents126
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4758256 A1 | 2026-06-17 | 61 | P23582 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 3615 | P23582 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 9472 | P23582 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 9473 | P23582 | Espacenet |
| JP 2025138725 A | 2025-09-25 | 2005 | P23582 | Espacenet |
| JP 2025138725 A | 2025-09-25 | 2793 | P23582 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 7167 | P23582 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 7167 | P23582 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 3615 | P23582 | Espacenet |
| JP 2025510608 A | 2025-04-15 | 1 | P23582 | Espacenet |
1 to 10 of 126
See all 126 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants623
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | NPPC papers | Newest fiscal year |
|---|---|---|---|
| ZIAHD000640 | Regulation Of Childhood Growth | 5 | 2025 |
| R01HL158548 | Novel Therapeutics for Cardiovascular Disease | 4 | 2025 |
| P30CA014195 | Cancer Center Support Grant (CCSG) | 3 | 2025 |
| R01HL084155 | Human Cardiorenal Syndrome | 3 | 2025 |
| T32AR007612 | Minnesota Muscle Training Program | 3 | 2025 |
| P20GM109036 | Tulane COBRE for Clinical and Translational Research in Cardiometabolic Diseases | 2 | 2025 |
| R01GM029090 | Myosin Gene Diversity and Function | 2 | 2025 |
| R01HD072929 | Optimal Oxygenation in Neonatal Lung Injury | 2 | 2025 |
| R35HL150698 | New Mechanistic Insights & Therapeutic Applications of Megakaryocytes/Platelets | 2 | 2025 |
| T32AR076951 | Training Program/Rheumatic Diseases | 2 | 2025 |
1 to 10 of 623Source NIH's project files
See all 623 nih grantsPapers1,757
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Consensus statement on the management of Achondroplasia in the Middle East. | Front Endocrinol (Lausanne) | 2026 | 42823987 | PubTator, text mining | PubMed |
| The relationship between maternal c-type natriuretic peptide levels and fetal growth restriction. | Ir J Med Sci | 2026 | 42782584 | PubTator, text mining | PubMed |
| A Phase 3 Trial of Vosoritide in Children with Hypochondroplasia. | NEJM Evid | 2026 | 42713641 | PubTator, text mining | PubMed |
| Slipped Capital Femoral Epiphysis during Vosoritide Therapy for Short Stature: A Case Series. | Horm Res Paediatr | 2026 | 42678892 | PubTator, text mining | PubMed |
| Real-World Evidence on the Effectiveness and Safety of Vosoritide in Latin American Patients With Achondroplasia (EVOLAC). | Am J Med Genet A | 2026 | 42675811 | PubTator, text mining | PubMed |
| The First Successful Capacitation In Vitro Maturation of Oocyte in Indonesia: A Promising Strategy to Enhance IVF Accessibility for Infertile Couples. | J Reprod Infertil | 2026 | 42632963 | PubTator, text mining | PubMed |
| Tetrameric neutralization and orthogonal catalytic hairpin assembly for direct differential detection of microRNA. | Anal Chim Acta | 2026 | 42508916 | PubTator, text mining | PubMed |
| Beyond the pump: integrating the heart's endocrine function into early medical education. | Med Educ Online | 2026 | 42455767 | PubTator, text mining | PubMed |
| E2 ubiquitin-conjugating enzyme UBE2T in mural granulosa cells regulates ovine oocyte maturation via the mTOR-CNP signaling pathway. | Theriogenology | 2026 | 42419071 | PubTator, text mining | PubMed |
| Spatial and Molecular Parameters of Pre-OPU Ovarian Follicles and Their Association with Embryo Developmental Competence in Assisted Reproductive Technology. | Int J Mol Sci | 2026 | 42353000 | PubTator, text mining | PubMed |
1 to 10 of 1,757
See all 1,757 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/4880
GET https://conductscience.org/api/genes/v1/4880/patents?page=2